Carefreeing

Beijing Carefreeing Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative small molecule therapeutics. The company's research efforts are primarily concentrated on the central nervous system (CNS) and oncology, aiming to provide novel solutions for diseases with high unmet medical needs. Its lead product candidate, KRN-103, is a selective monoamine oxidase B (MAO-B) inhibitor currently undergoing Phase 3 clinical trials for the treatment of Parkinson's disease. Carefreeing also maintains a growing pipeline of other candidates, including KRN-101 for major depressive disorder and KRN-105 for solid tumors, supported by a robust internal R&D platform.